Devyser Diagnostics Bilan de santé

Santé financière contrôle des critères 5/6

Devyser Diagnostics possède un total de capitaux propres de SEK349.0M et une dette totale de SEK500.0K, ce qui porte son ratio d'endettement à 0.1%. Son actif total et son passif total sont SEK462.9M et de SEK113.9M.

Informations clés

0.1%

Ratio d'endettement

SEK 500.00k

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	SEK 171.40m
Fonds propres	SEK 349.00m
Total du passif	SEK 113.90m
Total des actifs	SEK 462.90m

Mises à jour récentes de la santé financière

Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business

Feb 22

Recent updates

Analysts Just Made A Substantial Upgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) Forecasts

Jun 14

Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 27% But Many Are Still Ignoring The Company

Mar 20

Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported And Analysts Have Been Cutting Their Estimates

Feb 23

Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business

Feb 22

Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 28% But Many Are Still Ignoring The Company

Dec 09

These Analysts Just Made An Incredible Downgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) EPS Forecasts

Aug 30

Devyser Diagnostics AB (publ) (STO:DVYSR) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 14

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de DVYSR ( SEK258.9M ) dépassent ses passifs à court terme ( SEK61.5M ).

Passif à long terme: Les actifs à court terme de DVYSR ( SEK258.9M ) dépassent ses passifs à long terme ( SEK52.4M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: DVYSR dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de DVYSR a été réduit de 23.7% à 0.1% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: DVYSR dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: Données insuffisantes pour déterminer si DVYSR dispose de suffisamment de piste de trésorerie si son flux de trésorerie disponible continue de croître ou de diminuer en fonction des taux historiques.

Devyser Diagnostics Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business

Recent updates

Devyser Diagnostics AB (publ), Annual General Meeting, May 14, 2025

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 18%

Chief Executive Officer recently bought kr324k worth of stock

Second quarter 2024 earnings released: kr1.41 loss per share (vs kr0.90 loss in 2Q 2023)

New minor risk - Shareholder dilution

Chief Executive Officer recently sold kr5.5m worth of stock

Analysts Just Made A Substantial Upgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) Forecasts

Devyser Diagnostics AB (publ) Appoints Thomas Eklund as Member of the Board of Directors

Chief Executive Officer recently bought kr299k worth of stock

First quarter 2024 earnings released: kr0.75 loss per share (vs kr1.23 loss in 1Q 2023)

Devyser Receives IVDR Approval for Post-Transplant Monitoring Software

Full year 2023 earnings: EPS misses analyst expectations

Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 27% But Many Are Still Ignoring The Company

Consensus estimates of losses per share improve by 66%

Devyser Diagnostics AB (publ) Announces Study Publication Demonstrating dd-cfDNA Detection in Dual Donor Kidney Transplant Patient

Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported And Analysts Have Been Cutting Their Estimates

Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Insider selling

Devyser Diagnostics AB (Publ) Announces Michael Uhlin, CSO Joins Management Team as of February 1, 2024

Devyser Diagnostics AB (publ) to Report Fiscal Year 2023 Final Results on Apr 11, 2024

Devyser Diagnostics AB (publ) to Report Q1, 2024 Results on May 08, 2024

Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 28% But Many Are Still Ignoring The Company

Chief Executive Officer recently bought kr1.5m worth of stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Devyser Diagnostics AB (publ), Annual General Meeting, May 14, 2024

Consensus estimates of losses per share improve by 29%

Independent Director recently bought kr1.1m worth of stock

Consensus revenue estimates fall by 11%

These Analysts Just Made An Incredible Downgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) EPS Forecasts

New minor risk - Profitability

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Devyser's Ngs Products for Monitoring of Kidney and Stem Cell Transplanted Patients Receive IVDR Approvals

Devyser Launches Two New Genetic Testing Solutions for Hereditary Cancer

Devyser Announces its Deputy CEO and Founder Ulf Klangby Moves to Advisory Role

Chief Executive Officer recently bought kr105k worth of stock

Devyser Diagnostics AB Announces Approval of Devyser's RHD Product in Canada

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to kr1.89 loss

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 1,989%

Less than half of directors are independent

Third quarter 2022 earnings released: kr0.55 loss per share (vs kr0.87 loss in 3Q 2021)

Devyser Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

Devyser Diagnostics AB (publ) Appoints John Murad as Vice President and General Manager in the US

Consensus EPS estimates fall by 66%

Second quarter 2022 earnings released: kr0.90 loss per share (vs kr0.94 loss in 2Q 2021)

Devyser Diagnostics AB (publ) to Report Q3, 2023 Results on Nov 09, 2023

Devyser Diagnostics AB (Publ) Appoints Camilla Wiberg as Chief HR Officer

Less than half of directors are independent

Devyser Diagnostics AB (publ) (STO:DVYSR) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Devyser Diagnostics AB (publ), Annual General Meeting, May 11, 2022

Less than half of directors are independent

Devyser Diagnostics AB (publ) Appoints Theis Kipling as Chief Commercial Officer

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Devyser Diagnostics AB (publ) to Report Q4, 2021 Results on Feb 24, 2022

Devyser Diagnostics AB (publ) (OM:DVYSR) agreed to acquire the remaining 70.1% stake in Smartseq S.R.L. from its three founders for €0.84 million.

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines